EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

RUNX1 isoform disequilibrium promotes the development of trisomy 21–associated myeloid leukemia

Sofia Gialesaki, Daniela Bräuer-Hartmann iD, Hasan Issa, Raj Bhayadia, Oriol Alejo-Valle, Lonneke Verboon, Anna-Lena Schmell iD, Stephanie Laszig, Enikő Regényi, Konstantin Schuschel, Maurice Labuhn, Michelle Ng iD und 13 weitere

Blood · 09.03.2023 · 141 (10) · 1105-1118

DOI: 10.1182/blood.2022017619 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Blood, erschienen am 09.03.2023. Verfasst von Sofia Gialesaki und 24 weiteren Autor:innen. Beteiligte Einrichtung: Pediatric Hematology and Oncology, Hannover Medical School, Hannover, Germany. Hauptthemen laut MEDLINE: Core Binding Factor Alpha 2 Subunit, Down Syndrome, Leukemia, Myeloid. Die Arbeit wurde bisher 51-mal zitiert (Crossref) und nennt 61 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Gain of chromosome 21 (Hsa21) is among the most frequent aneuploidies in leukemia. However, it remains unclear how partial or complete amplifications of Hsa21 promote leukemogenesis and why children with Down syndrome (DS) (ie, trisomy 21) are particularly at risk of leukemia development. Here, we propose that RUNX1 isoform disequilibrium with RUNX1A bias is key to DS-associated myeloid leukemia (ML-DS). Starting with Hsa21-focused CRISPR–CRISPR-associated protein 9 screens, we uncovered a strong and specific RUNX1 dependency in ML-DS cells. Expression of the RUNX1A isoform is elevated in patients with ML-DS, and mechanistic studies using murine ML-DS models and patient-derived xenografts revealed that excess RUNX1A synergizes with the pathognomonic Gata1s mutation during leukemogenesis by displacing RUNX1C from its endogenous binding sites and inducing oncogenic programs in complex with the MYC cofactor MAX. These effects were reversed by restoring the RUNX1A:RUNX1C equilibrium in patient-derived xenografts in vitro and in vivo. Moreover, pharmacological interference with MYC:MAX dimerization using MYCi361 exerted strong antileukemic effects. Thus, our study highlights the importance of alternative splicing in leukemogenesis, even on a background of aneuploidy, and paves the way for the development of specific and targeted therapies for ML-DS, as well as for other leukemias with Hsa21 aneuploidy or RUNX1 isoform disequilibrium.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Core Binding Factor Alpha 2 SubunitDown SyndromeLeukemia, MyeloidAnimalsChildHumansMiceAneuploidyProtein IsoformsTrisomy

Substanzen

Core Binding Factor Alpha 2 SubunitProtein IsoformsRUNX1 protein, human

Autor:innen und Institutionen

  • Pediatric Hematology and Oncology, Hannover Medical School, Hannover, Germany.
  • Pediatric Hematology and Oncology, Martin Luther University Halle-Wittenberg, Halle, Germany.
  • Department of Pediatrics, Goethe University Frankfurt, Frankfurt am Main, Germany.
  • Max Planck Institute for Molecular Genetics, Berlin, Germany.
  • Department of Pharmaceutical Chemistry and Bioanalytics, Institute of Pharmacy, Martin Luther University Halle-Wittenberg, Halle, Germany.
  • Institute of Molecular Medicine, Martin Luther University Halle-Wittenberg, Halle, Germany.

ORCID-Profile: Daniela Bräuer-Hartmann, Anna-Lena Schmell, Michelle Ng, Markus Glaß, Farina Josepha Strüwe, Dirk Reinhardt, Jan-Henning Klusmann

Zitieren

APA

Gialesaki, S., Bräuer-Hartmann, D., Issa, H., Bhayadia, R., Alejo-Valle, O., Verboon, L., Schmell, A. L., Laszig, S., Regényi, E., Schuschel, K., Labuhn, M., Ng, M., Winkler, R., Ihling, C., Sinz, A., Glaß, M., Hüttelmaier, S., Matzk, S., Schmid, L., …, & Klusmann, J. H. (2023). RUNX1 isoform disequilibrium promotes the development of trisomy 21–associated myeloid leukemia. Blood, 141(10), 1105-1118. https://doi.org/10.1182/blood.2022017619

Vancouver

Gialesaki S, Bräuer-Hartmann D, Issa H, Bhayadia R, Alejo-Valle O, Verboon L, et al. RUNX1 isoform disequilibrium promotes the development of trisomy 21–associated myeloid leukemia. Blood. 2023;141(10):1105-1118. doi:10.1182/blood.2022017619

BibTeX
@article{Gialesaki2023,
  author = {Gialesaki, Sofia and Bräuer-Hartmann, Daniela and Issa, Hasan and Bhayadia, Raj and Alejo-Valle, Oriol and Verboon, Lonneke and Schmell, Anna-Lena and Laszig, Stephanie and Regényi, Enikő and Schuschel, Konstantin and Labuhn, Maurice and Ng, Michelle and Winkler, Robert and Ihling, Christian and Sinz, Andrea and Glaß, Markus and Hüttelmaier, Stefan and Matzk, Sören and Schmid, Lena and Strüwe, Farina Josepha and Kadel, Sofie-Katrin and Reinhardt, Dirk and Yaspo, Marie-Laure and Heckl, Dirk and Klusmann, Jan-Henning},
  title = {RUNX1 isoform disequilibrium promotes the development of trisomy 21–associated myeloid leukemia},
  journal = {Blood},
  year = {2023},
  volume = {141},
  number = {10},
  pages = {1105--1118},
  doi = {10.1182/blood.2022017619}
}
Kostenlos starten →